Allarity Therapeutics Reports Q2 2026 Financial Results

What Happened
On August 14, 2026, Allarity Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release. The announcement was reported in a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and the press release is attached as Exhibit 99.1 to the filing. The company notes the information in this Current Report is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.

Key Details

• Filing date: August 14, 2026 (Form 8-K).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Press release attached as Exhibit 99.1 contains the reported results.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) is included with the filing.

Why It Matters
This 8-K provides a timely update on Allarity’s quarterly results (earnings and other financial measures) for Q2 2026; investors should review the attached press release for the company’s reported revenue, profit/loss, cash position, and any commentary management provided. Because the filing states the release is not "filed" under Section 18, its legal incorporation into other filings is limited — investors should also watch for the company’s upcoming periodic reports (e.g., Form 10-Q) for the complete financial statements and formal disclosures.